Sunovion Receives Complete Response Letter from FDA for Apomorphine Sublingual Film (APL-130277)

MARLBOROUGH, Mass.--(BUSINESS WIRE) January 30, 2019 --Sunovion Pharmaceuticals Inc. (Sunovion) announced today that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) for the New Drug Application (NDA) for...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news